NCT05291234: An ongoing trial by AbbVie
This trial is ongoing. It must report results 11 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05291234 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects With Early Alzheimer's Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 15, 2022 |
| Completion date | Nov. 19, 2025 |
| Required reporting date | Nov. 19, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |